DÄ internationalArchive15/2007Metastatic Bladder Carcinoma

Review article

Metastatic Bladder Carcinoma

Dtsch Arztebl 2007; 104(15): A-1024

Jakse, G; Stöckle, M; Lehmann, J; Otto, T; Krege, S; Rübben, H

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Sternberg CN, Yagoda A, Scher HI et al.: Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse, Cancer 1989; 64: 2448–58. MEDLINE
2. DeMulder PH, Debruyne FM, Keizer HJ et al.: Randomized phase II study of methotrexate (M), cisplatin (C) and methotrexate, cisplatin and vinblastine (V) in patients with advanced transitional carcinoma of the bladder. Eur Urol 1990; 18 (Suppl. 1): 5.
3. Mead GM, Russell M, Clark P et al.: A randomised trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br J Cancer 1998; 78: 1067–75. MEDLINE
4. Logothetis CJ, Dexeus FH, Finn L et al.: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8: 1050–5. MEDLINE
5. Von der Maase H, Hansen SW, Roberts JT et al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomised, multinational, multicenter phase III study. J Clin Oncol 2000; 18: 3068–77. MEDLINE
6. Sternberg CN, de Mulder PHM, Schornagel JH et al.: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol 2001; 19: 2638–46. MEDLINE
7. Dreicer R, Manola J, Roth BJ et al.: Phase III trial of methotrexate, vinblastine, doxorubicin and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004; 100:1639–45. MEDLINE
8. Bamias A, Aravantinos G, Deliveliotis C: Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomised, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004; 22: 220–8. MEDLINE
9. Burch PA, Richardson RL, Cha SS et al.: Phase II trial of combination paclitaxel and cisplatin in advanced urothelial carcinoma (UC). J Urol 2000; 164: 1538–42. MEDLINE
10. Small EJ, Lew D, Redman BG et al.: Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol 2000; 18: 2537–44. MEDLINE
11. Meluch AA, Greco FA, Burris HA et al.: Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2001; 19: 3018–24. MEDLINE
12. Krege S, Rembrink V, Börgermann Ch et al.: Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase II study. J Urol 2001; 165: 67–71. MEDLINE
13. Bajorin DF, McCaffrey JA, Dodd PM et al.: Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: a final report of a phase II trial evaluating two dosing schedules. Cancer 2000; 88: 1671–8. MEDLINE
14. Bellmunt J, Guillem V, Paz-Ares L et al.: Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000; 18: 3247–55. MEDLINE
15. Von der Maase H, Sengelov L, Roberts JT et al.: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602. MEDLINE
16. Geller NL, Sternberg CN, Penenberg D et al.: Prognostic factors for survival of patients with advanced urothelial tumors treated with Methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1991; 67: 1525–31. MEDLINE
17. Dodd PM, McCaffrey JA, Herr H et al.: Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin and, cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 1999; 17: 2546–51. MEDLINE
18. Bajorin DF, Dodd PM, Mazumbar M et al.: Long-term survival in metastatic transitional-cell carcinoma: prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17: 3173–81. MEDLINE
19. Bellmunt J, Albanell J, Paz-Ares L et al.: Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin and gemcitabine. Cancer 2002; 95: 751–7. MEDLINE
20. Sweeney P, Millikan R, Donat M et al.: Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection In metastatic transitional cell carcinoma of the bladder?J Urol 2003; 169: 2113–7. MEDLINE
21. Siefker-Radtke AO, Walsh GL, Pisters LL et al.: Is there a role for surgery in the management of metastatic urothelial cancer? The M.D. Anderson experience. J Urol 2004; 171: 145–8. MEDLINE
22. Otto T, Krege S, Suhr J, Rübben H: Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance status: a phase II trial. Urology 2001; 57: 55–9. MEDLINE
23. Otto T, Suhr J, Krege S et al.: Surgical treatment of disseminated peritoneal metastases from urological cancer: results from a prospective study. BJU Int 2002; 90: 823–7. MEDLINE
24. Hussain M, Petrylak DP, Dunn R et al.: Trastuzumab, paclitaxel, carboplatin and gemcitabine in advanced HER2-positive urothelial carcinoma: Results of a multi-center phase II NCI trial. J Clin Oncol 2005; 23: 379 (abstract 4507). MEDLINE
25. Wülfing C, Machiels J, Richel D et al.: A single arm, multicenter, open label, phase II study of lapatinib as 2-line treatment of patients with locally advanced/metastatic transitional cell carcinoma of the urothelial tract. J Clin Oncol 2005; 23: 422 (abstract 4677).